Table 2.
Differentially expressed genes up- and downregulated related to Dopaminergic, GABAergic and Glutamatergic synapse pathways.
| Gene | Name | Fold Change CBG 1 µM |
Fold Change CBG 5 µM |
Fold Change CBD 1 µM |
Fold Change CBD 5 µM |
Pathway |
|---|---|---|---|---|---|---|
| ADCY5 | adenylate cyclase 5 | 5.86 | 4.74 | 5.25 | 6.03 | Dopaminergic, GABAergic, Glutamatergic synapse |
| ADCY9 | adenylate cyclase 9 | −1.15 | −1.28 | −1.1 | −1.31 | GABAergic, Glutamatergic synapse |
| AKT1 | thymoma viral proto-oncogene 1 | 0.80 | 0.74 | 0.84 | 0.96 | Dopaminergic synapse |
| ATF4 | activating transcription factor 4 | 0.71 | 0.74 | 0.80 | 0.76 | Dopaminergic synapse |
| CAMK2B | calcium/calmodulin-dependent protein kinase II, beta | −1.33 | −1.25 | −1.02 | −1.29 | Dopaminergic synapse |
| CLOCK | circadian locomotor output cycles kaput | −1.59 | −1.53 | −1.41 | −1.42 | Dopaminergic synapse |
| CREB1 | cAMP responsive element binding protein 1 | −1.08 | −0.98 | −0.95 | −1.23 | Dopaminergic synapse |
| DLGAP1 | DLG associated protein 1 | 1.61 | 1.56 | 1.32 | 1.26 | Glutamatergic synapse |
| DRD2 | dopamine receptor D2 | −0.71 | −0.74 | −0.81 | −1.08 | Dopaminergic synapse |
| DRD4 | dopamine receptor D4 | 1.61 | 2.03 | 1.36 | 1.84 | Dopaminergic synapse |
| GNAI2 | guanine nucleotide binding protein (G protein), alpha inhibiting 2 | 0.86 | 0.95 | 0.76 | 0.77 | Dopaminergic, GABAergic, Glutamatergic synapse |
| GNAL | guanine nucleotide binding protein, alpha stimulating, olfactory type | −1.64 | −5.79 | −2.32 | −1.74 | Dopaminergic synapse |
| GNB4 | guanine nucleotide binding protein (G protein), beta 4 | 1.46 | 1.14 | 0.74 | 1.16 | Dopaminergic, GABAergic, Glutamatergic synapse |
| HAP1 | huntingtin-associated protein 1 | 1.14 | 0.93 | 0.86 | 1.41 | GABAergic synapse |
| PLD1 | phospholipase D1 | −1.12 | −0.83 | −2.39 | −1.22 | Glutamatergic synapse |
| PPP3R1 | protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) | −1.75 | −1.45 | −0.97 | −1.7 | Glutamatergic synapse |
| PRKCA | protein kinase C, alpha | 0.97 | 1.09 | 0.86 | 0.95 | Dopaminergic, GABAergic, Glutamatergic synapse |
| PRKCB | protein kinase C, beta | −2.71 | −2.83 | −4.81 | −1.49 | Dopaminergic, GABAergic, Glutamatergic synapse |
| SHANK1 | SH3 and multiple ankyrin repeat domains 1 | −1.22 | −0.76 | −0.86 | −1.42 | Glutamatergic synapse |
| SLC1A2 | solute carrier family 1 (glial high affinity glutamate transporter), member 2 | −0.84 | −0.75 | −0.72 | −0.93 | Glutamatergic synapse |
| SLC18A1 | solute carrier family 18 (vesicular monoamine), member 1 | −1.49 | −3.61 | −6.03 | −1.58 | Dopaminergic synapse |
| SLC32A1 | solute carrier family 32 (GABA vesicular transporter), member 1 | 1.1 | 0.85 | 0.92 | 0.96 | GABAergic synapse |
| SLC38A1 | solute carrier family 38, member 1 | −1.12 | −0.91 | −1.64 | −1.33 | GABAergic and Glutamatergic synapse |
Each gene was associated with the fold change resulting in the analysis of CBG at dose of 1 and 5 µM against control (“Fold Change CBG 1 µM” and “Fold Change CBG 5 µM”) and CBD at dose of 1 and 5 µM (“Fold Change CBD 1 µM” and “Fold Change CBD 5 µM”). Furthermore, the column “Pathway” shows if the gene plays a role in the Dopaminergic, GABAergic or Glutamatergic synapse pathways.